RBB

Mihael Raveggi

Mihael Raveggi has over twenty years of experience advising clients on EU and multi-jurisdictional mergers across a wide range of industries.

Mihael is recognised as “an authority on high-profile EU mergers and Article 101 and 102 cases” by Lexology’s Who’s Who Legal. Sources call him “a standout” who is “very responsive, great to work with and always on top of the data”. Mihael Raveggi has joined RBB Economics in 2002 and is an Associate Principal in the Milan and Brussels offices.

In his role as a consultant competition economist, Mihael has over 20 years’ experience advising clients and preparing submissions in merger proceedings for the European Commission and for other major jurisdictions.

Mihael has played a central and decisive role in many of the largest and most complex Phase II merger investigations at the European Commission over the last decade.

His experience also includes Article 101 and 102 cases. Mihael has worked for a baby powder milk producer (Italy) and a banana importer (EC) in 101 cases in front of national Competition Authorities. He also worked on estimating third party damages.

Mihael has worked for Google on a study to estimate the value of Youtube to the music industry. The results have been published online.

Mihael taught competition policy at Sciences Po for over ten years, regularly holds presentations at law firms and has spoken at numerous conferences.

Mihael holds dual Italian and Slovene nationality and is fluent in English and Italian. He has also worked in French and Slovene.

Selected Cases

  • XSYS/MacDermid

    Merger, Global

  • Reliance Industries / Disney

    JV, India

  • Booking / eTraveli

    Conglomerate Merger, EU

  • Aon/Willis Tower Watson

    Merger, Global

  • Bayer

    Merger, Global

  • Tronox

    Merger, Global

  • AB InBev

    Merger, Global

  • Youtube

    Economic valuation of music industry, EU

A global network of experienced experts

Our 230-strong, multi-lingual team, spread across 16 offices, has managed over 3,000 cases in 120+ countries, advising on more than one-third of EU Phase II cases in the last 5 years.